# Cambridge Innovation Capital

> Cambridge Innovation Capital is a VC fund backing Biotechnology. See 104 investments, check sizes, portfolio and contact details. Updated Aug 2026.

- Type: VC Fund
- Location: Cambridge, United Kingdom
- Total investments: 104
- Last investment: Jun 2026
- Lead investor: 36%
- Last fund: Feb 2025
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/company/cambridge-innovation-capital-plc
- X (Twitter): https://twitter.com/cic_vc
- Website: https://www.cic.vc/

Cambridge Innovation Capital is a VC fund in Cambridge focused on Biotechnology and Health Care. Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

## Contacts

5 contacts available for Cambridge Innovation Capital. Shizune tracks 10 team members at Cambridge Innovation Capital. Sign up free to unlock them: https://app.shizune.co/sign-up/investor-profiles/find-team-emails/cambridge-innovation-capital?utm_source=investor_profile

## Round sizes

| Stage | Round size |
| --- | --- |
| Seed | $2.5M–$31M |
| Series A | $2.6M–$73M |
| Series B | $8.5M–$66M |

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 24 | 23% |
| Health Care | 14 | 13% |
| Medical | 11 | 11% |
| Therapeutics | 11 | 11% |
| Software | 10 | 10% |

64 industries tracked in total.

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 26 | 25% |
| Series B | 23 | 22% |
| Seed | 16 | 15% |
| Funding Round | 11 | 11% |
| Series C | 7 | 7% |

9 stages tracked in total.

### Country

| Country | Investments | Share |
| --- | --- | --- |
| United Kingdom | 42 | 40% |
| United States | 4 | 4% |
| Ireland | 1 | 1% |

## Team

| Name | Title | Investments | Profile |
| --- | --- | --- | --- |
| Anne Horgan | Partner | 3 | https://shizune.co/investors/profile/anne-horgan |
| Damian Crowther | Entrepreneur In Residence | 0 | https://shizune.co/investors/profile/damian-crowther |
| Edward Benthall | Chairman | 2 | https://shizune.co/investors/profile/edward-benthall |
| Humphrey Battcock | Independent Non-executive Director | 0 | https://shizune.co/investors/profile/humphrey-battcock |
| Ian Jauncey | Operating Partner | 0 | https://shizune.co/investors/profile/ian-jauncey |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $14M | Seed | Jun 23, 2026 |  |
| Trent AI | Trent AI creates AI applications and agent security management software. It aids in risk assessment and mitigation in systems utilizing autonomous or semi-autonomous software agents. The company's technology monitors agent activity across APIs, tools, and workflows. It continuously assesses security posture via iterative scanning andcontextual understanding of system architectures. | $12.7M | Seed | Apr 07, 2026 |  |
| Immutrin | Immutrin is a biotechnology company developing next‑generation antibody therapies designed to clear systemic amyloid deposits and reverse amyloidosis, this company lead asset targets ATTR cardiomyopathy, a severe and progressive form of amyloidosis, and its antibody represents a potential best‑in‑class treatment engineered to selectively andspecifically remove established amyloid fibrils. | $87.1M | Series A | Mar 24, 2026 |  |
| BeyondMath | AI-first approach to simulating the physical world | $10M | Seed | Feb 25, 2026 |  |
| T-Therapeutics | T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. . | $32M | Series A | Nov 13, 2025 |  |
| Sortera Bio | Sortera Bio operates as a biotechnology company. Sortera is committed to providing revolutionary solutions in biologics discovery. | $10.2M | Pre-Seed | Jun 05, 2025 |  |
| TRIMTECH Therapeutics | TRIMTECH Therapeutics is a biotech organization that treats neurodegenerative illnesses by using targeted protein degradation (TPD). | $31M | Seed | Mar 05, 2025 |  |
| Salience Labs | Salience Labs is building a hybrid photonic-electronic chip for AI. We have designed a massively parallel, ultra-high-throughput Photonic Tensor Processing Unit. Photonics allows data to be modulated at up to 100 GHZ, and allows for high levels of parallelization using multiplexing. We integrate this photonic unit into a SoC architecture designedto exploit its high throughput for AI inference. Salience Labs technology is based on decades of research collaboration between Oxford University and the University of Münster, Germany. | $30M | Series A | Feb 07, 2025 |  |
| Forefront RF | Forefront RF is a fabless semiconductor company. | $20.8M | Series A | Nov 07, 2024 |  |
| Epitopea | Epitopea is a transatlantic biotechnology company developing transformational immunotherapies to treat cancer by targeting a new class of antigens that are broadly shared between patients with the same cancer indication. Cryptigen™ TSAs are discovered by a proprietary approach deploying immunopetidomics, mass spectrometry, genomics, andbioinformatics, which allows the identification of conserved, aberrantly-expressed, tumour-specific antigens, hidden in cancer's 'junk' DNA. These hidden Cryptigen™ TSAs have been identified by research led by Drs. Claude Perreault and Pierre Thibault at the Institute for Research in Immunology and Cancer at Université de Montréal. | $31M | Seed | Oct 24, 2024 |  |

10 of 104 investments shown.

## Co-investors
- [Parkwalk Advisors](https://shizune.co/investors/profile/parkwalk-advisors) — VC Fund, 16 deals together
- [University of Cambridge Enterprise](https://shizune.co/investors/profile/university-of-cambridge-enterprise) — VC Fund, 15 deals together
- [Amadeus Capital Partners](https://shizune.co/investors/profile/amadeus-capital-partners) — VC Fund, 14 deals together
- [Octopus Ventures](https://shizune.co/investors/profile/octopus-ventures) — VC Fund, 9 deals together
- [Tencent](https://shizune.co/investors/profile/tencent) — VC Fund, 8 deals together
- [ARCH Venture Partners](https://shizune.co/investors/profile/arch-venture-partners) — VC Fund, 7 deals together

## Similar investors

### Similar industry
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [SV Angel](https://shizune.co/investors/profile/sv-angel) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

### Similar country
- [SFC Capital](https://shizune.co/investors/profile/startup-funding-club) — VC Fund
- [Fuel Ventures](https://shizune.co/investors/profile/fuel-ventures-fund) — VC Fund
- [Business Growth Fund](https://shizune.co/investors/profile/business-growth-fund) — VC Fund

## Featured in investor lists
- [Health Care Investors in United Kingdom](https://shizune.co/investors/health-care-investors-united-kingdom)
- [Health Care VC Funds in United Kingdom](https://shizune.co/investors/health-care-vc-funds-united-kingdom)
- [Biotechnology VC Funds in Europe](https://shizune.co/investors/biotechnology-vc-funds-europe)
- [Biotech Investors in Europe](https://shizune.co/investors/biotech-investors-europe)
- [Biotech VC Funds in Europe](https://shizune.co/investors/biotech-vc-funds-europe)
- [Biotechnology Investors in Europe](https://shizune.co/investors/biotechnology-investors-europe)

## FAQ

### What does Cambridge Innovation Capital invest in?

Cambridge Innovation Capital invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 104 investments tracked by Shizune back companies in United Kingdom. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### What is Cambridge Innovation Capital's check size?

Cambridge Innovation Capital typically joins rounds of $2.5M–$31M at Seed, $2.6M–$73M at Series A and $8.5M–$66M at Series B. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds Cambridge Innovation Capital participates in.

### How do I contact Cambridge Innovation Capital?

Public channels for Cambridge Innovation Capital include LinkedIn, X (Twitter) and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.

### Who are the partners at Cambridge Innovation Capital?

The team at Cambridge Innovation Capital includes Anne Horgan (Partner), Damian Crowther (Entrepreneur In Residence) and Edward Benthall (Chairman), among 10 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co